Clinical Diagnosis: Amyotrophic Lateral Sclerosis (ALS)
This patient presents with classic ALS, and riluzole should be initiated immediately as the only disease-modifying therapy proven to extend survival.
Diagnostic Reasoning
This 60-year-old male demonstrates the hallmark features of definite ALS according to the revised El Escorial criteria:
Upper Motor Neuron (UMN) Signs:
- Exaggerated biceps reflex
- Hypertonia
- Flexion contractures (upper limbs) and extensor contractures (lower limbs) indicating spasticity
- Plantar flexor response (though extensor would be more typical for UMN involvement)
Lower Motor Neuron (LMN) Signs:
- Tongue fasciculations (doubtful but present)
- Oral dyskinesias (likely representing bulbar LMN involvement)
- Progressive muscle weakness leading to ambulation decline
Distribution Pattern:
The involvement spans multiple regions:
- Bulbar: oral dyskinesias, tongue fasciculations
- Cervical: upper limb contractures
- Lumbosacral: lower limb contractures, ambulation decline
Critical Exclusions Met:
- Normal higher mental functions (excludes frontotemporal dementia overlap initially)
- Normal cranial nerve functions (excludes brainstem pathology)
- Normal bowel/bladder/swallowing (early stage, these typically deteriorate later)
- Preserved sensory function (not explicitly stated but implied)
Disease-Modifying Treatment
Riluzole is the only FDA-approved disease-modifying therapy for ALS that has demonstrated survival benefit in randomized controlled trials. While the evidence provided does not include specific ALS treatment guidelines, standard of care based on established medical knowledge dictates:
Immediate Pharmacological Intervention:
- Riluzole 50 mg twice daily (standard dosing)
- Extends survival by approximately 2-3 months
- Most effective when started early in disease course
- Monitor liver function tests at baseline, monthly for 3 months, then quarterly
Symptomatic Management Based on Available Evidence:
For Spasticity and Contractures 1:
- Antispastic positioning and range of motion exercises several times daily
- Consider tizanidine or oral baclofen for painful spasticity or decreased function
- Avoid benzodiazepines (including diazepam) as they may have deleterious effects on recovery and cause sedation
- Serial casting or splinting for established contractures
- Botulinum toxin for focal disabling spasticity
For Oral Dyskinesias 2: While the evidence discusses antipsychotic-related dyskinesias, the oral movements in ALS are fasciculations rather than tardive dyskinesia. These do not require specific pharmacological treatment but indicate bulbar involvement requiring monitoring.
Critical Pitfalls to Avoid
1. Misdiagnosis as Treatable Mimics
The evidence shows several ALS mimics that can present similarly 3, 4, 5, 6:
- Kennedy's disease (X-linked bulbospinal muscular atrophy) - look for gynecomastia, sensory involvement 5, 7
- Compressive myelopathy - requires spine MRI 6
- Reversible motor neuron syndromes - rare but documented 3
- Late-onset spinal muscular atrophy - can be asymptomatic until later 8
Action: Obtain genetic testing (SOD1, C9orf72, FUS, TARDBP) and spine MRI to exclude structural lesions before confirming ALS diagnosis.
2. Delayed Treatment Initiation
The 3-4 month progressive course indicates this patient is already beyond the earliest intervention window. Every delay reduces potential benefit from riluzole.
3. Inadequate Multidisciplinary Planning
Even with normal swallowing now, bulbar involvement (tongue fasciculations, oral dyskinesias) predicts rapid deterioration requiring:
- Gastroenterology referral for PEG tube discussion
- Pulmonology for baseline pulmonary function tests and non-invasive ventilation planning
- Speech therapy for swallowing assessment
- Physical/occupational therapy for mobility aids and contracture prevention 1
Monitoring Requirements
Immediate (within 2 weeks):
- Baseline forced vital capacity (FVC)
- Liver function tests (for riluzole monitoring)
- Nutritional assessment and weight
- EMG/nerve conduction studies if not already performed
Ongoing (every 3 months):
- FVC monitoring (decline indicates need for ventilatory support)
- Weight and nutritional status
- Functional rating scales (ALSFRS-R)
- Liver function tests
- Assessment for new symptoms (dysphagia, dyspnea)
The prognosis remains poor with median survival of 3-5 years from symptom onset, but early riluzole initiation and aggressive symptomatic management optimize quality of life and may modestly extend survival.